CD82 and ductal breast carcinoma in situ: In vivo, biopsies from patients diagnosed with breast ductal carcinoma in situ (DCIS; Supplementary Figure 1a) and pancreatic ductal adenocarcinoma (PDAC; Supplementary Figure 1b) were immunostained with antibodies against TIMP-1 and CD82.